

TRUE  **TARGET™**


TRUE  **DISCOVERY™**

TRUE  **SIGNATURE™**

TRANSFORMATIVE INSIGHTS FROM DISCOVERY TO CLINIC

Discover Deep and Innovative Insights to Advance Your
Research with the Power of Next-Generation Proteomics

A UNIQUE SUITE OF PROTEOMICS RESEARCH PLATFORMS FOR EVERY APPLICATION



TRUE TARGET™

Novel drug target identification and validation

The **Biognosys TrueTarget™ proteomics platform** uniquely addresses the most pressing challenges in early drug discovery by identifying on- and off-targets to accelerate and de-risk drug development throughout the pipeline. It is powered by Limited Proteolysis Mass Spectrometry (LiP-MS), a proprietary, patented chemoproteomics technology co-developed by Biognosys. TrueTarget™ is the

only tool to probe structural changes across the complete proteome with peptide-level resolution, providing unique insights into compound binding and target identification.

- ❖ **Applications**
DRUG TARGET DECONVOLUTION
DRUG TARGET VALIDATION

TRUE DISCOVERY™

Unbiased biological insights from tissue and biofluids

The **Biognosys TrueDiscovery™ platform** offers integrated proteomics solutions across the entire drug development pipeline. It is powered by Hyper Reaction Monitoring (HRM) mass spectrometry, a quantification technology co-invented and patented by Biognosys. TrueDiscovery™ is the only platform that searches the complete proteome of tissue and biofluids samples to quantify thousands of the most relevant proteins, including an unlimited number of proteoforms with unbeatable specificity on a large scale. The generated data are highly

reproducible and easily transferrable to clinical assays. Studies can be performed in a GLP certified and GCP compliant environment.

- ❖ **Applications**
BIOFLUID BIOMARKER DISCOVERY
TISSUE BIOMARKER DISCOVERY
MECHANISM OF ACTION STUDIES
PHOSPHOPROTEOME PROFILING
IMMUNOPEPTIDOME PROFILING

TRUE SIGNATURE™

Custom panels for absolute protein quantification


The **Biognosys TrueSignature™ platform** provides high-precision customizable proteomics panels for pharmacodynamic readouts and clinical biomarker monitoring. Parallel Reaction Monitoring (PRM) mass-spectrometry powers the platform, allowing complete customization and independence from affinity-based recognition and reagent availability. The TrueSignature™ panels offer an unprecedented level of multiplexing, enabling the simultaneous absolute quantification of

up to 100 proteins. TrueSignature panels can be developed within weeks and are available both as a standalone solution or an integrated solution, in which insights from TrueDiscovery studies guide the choice of proteins in the custom panel.

- ❖ **Applications**
PHARMACODYNAMIC BIOMARKERS
CLINICAL BIOMARKER PANELS

BIOGNOSYS: A LEADING INNOVATOR IN PROTEOMICS

As the leading inventor and innovator of mass spectrometry-based proteomics solutions, we offer industry-leading technology and actionable insights that you can trust to accelerate your research.



YOUR PARTNER THROUGHOUT THE RESEARCH JOURNEY

Biognosys is your trusted partner throughout the discovery and development journey with attentive pre-study consultation, high quality and timely data delivery, and insightful reporting.

Contact us at services@biognosys.com to discuss your specific study needs with one of our scientific or technical consultants.

At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that can dramatically improve human health. We enable life science researchers and drug hunters to look at the proteome from every angle with our versatile portfolio of proprietary proteomics services, software, and kits. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research.

biognosys.com

 **BIOGNOSYS**
NEXT GENERATION PROTEOMICS